Navigation Links
Codexis Names David Anton VP Bioindustrials R&D

REDWOOD CITY, Calif., March 25 /PRNewswire/ -- Codexis, Inc., today announced the appointment of David Anton, Ph.D. to the newly-created position of Vice President, Bioindustrials Research and Development. He joins Codexis from DuPont, where he was Venture Manager, Biofuels. He will report to Alan Shaw, Ph.D., President and CEO.

"Codexis targets major global energy and environmental markets where clean technology can make a significant impact," said Alan Shaw, Ph.D., President and CEO. "We are currently working with Shell in the development of biofuels, and expect to apply our technology to other potential new bioindustrial applications, such as carbon capture and storage, waste water purification and cleaner chemical manufacturing."

"Dr. Anton has over 25 years experience directing the development of new technology solutions and production processes at one of the world's largest science companies," Dr. Shaw added. "His experience as a scientist and venture manager in bioindustrials can make an important, immediate contribution to this important Codexis business. We are pleased to expand our management team with such a well known and broadly-experienced research executive."

Dr. Anton joined DuPont in 1983 and held a variety of senior research management positions across bioprocessing and biocatalysis. He led the process research, development and commercialization of several products, including 1,3 propanediol (a chemical intermediate used in a variety of industrial applications ranging from airplane deicing fluids to textiles and carpet). As Vice President, Research and Development for DuPont's joint venture with Tate and Lyle, he directed technology start-up activities for the first 100 million-pound plant for 1,3 propanediol, commissioned in Loudon, TN in 2006. As Venture Manager, Biofuels, he was global business lead for development of DuPont's advanced biofuel, biobutanol.

He holds a bachelor's degree in biochemistry from the University of California, Berkeley, and a Ph.D. in biochemistry from the University of Minnesota. He is a member of the joint DOE/USDA Biomass Research and Development Technology Advisory Committee.

Codexis, Inc., a clean technology company, is a leading developer of biocatalytic process technologies that can substantially reduce the cost of manufacturing across a broad range of industries. These technologies enable novel solutions for efficient, cost-effective and environmentally-friendly processes for pharmaceutical, energy and industrial chemical applications. In 2006, the U.S. EPA recognized Codexis with a Presidential Green Chemistry Challenge Award. Codexis is a registered trademark of Codexis, Inc. For more information, please visit

Contact: Justin Jackson,, Burns McClellan, 212-213-0006, or Lyn Christenson,, 650-421-8144.

SOURCE Codexis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
2. Rothwell, Wolf Elected to Codexis Board
3. Codexis Opens Singapore Laboratory
4. Bruce Pasternack Elected to Codexis Board
5. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
6. Codexis Appoints Singapore Laboratories Managing Director
7. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
8. Cato Research Names John Cline as President
9. Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors
10. Onyx Pharmaceuticals Names N. Anthony Coles, M.D. as President, Chief Executive Officer and Member of its Board of Directors
11. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
Post Your Comments:
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
Breaking Biology Technology:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):